Showing results (181-190 of 199) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd MaintenanceMaría-Victoria Mateos, Joaquin Martínez-López, Paula Rodriguez Otero, et al.
Blood|April 24, 2020
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myelomaCristina Perez, Cirino Botta, Aintzane Zabaleta, et al.
Hemasphere|April 25, 2025
High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapyAndrea Manubens, Bruno Paiva, Norma C Gutiérrez, et al.
Eclinicalmedicine|April 16, 2025
Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project)Paul Coppo, Michael Bubenheim, Ygal Benhamou, et al.
Blood|November 19, 2017
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myelomaThierry Facon, Meletios A Dimopoulos, Angela Dispenzieri, et al.
Blood|January 18, 2024
ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapyMaría-Eva Mingot-Castellano, Faustino García-Candel, Jorge Martínez-Nieto, et al.
Haematologica|July 11, 2024
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trialNoemí Puig, Cristina Agulló, Teresa Contreras, et al.
Blood Cancer Journal|March 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myelomaShaji Kumar, Sundar Jagannath, Katja C Weisel, et al.
Blood Cancer Journal|May 22, 2021
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trialNoemi Puig, Miguel T Hernández, Laura Rosiñol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2019
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple MyelomaBruno Paiva, Noemi Puig, Maria-Teresa Cedena, et al.
Pageof 20